Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02527629
Other study ID # 2015- 01, 20.07.2015
Secondary ID Grant Agreement
Status Completed
Phase
First received
Last updated
Start date September 2015
Est. completion date March 2019

Study information

Verified date May 2020
Source corlife
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Evaluation of decellularized human heart valves for aortic heart valve replacement in comparison to current valve substitutes.

Safety endpoints include cardiovascular adverse events, time to re-operation, re-intervention and explantation.

Efficacy endpoints include freedom from valve dysfunction and hemodynamic performance.


Description:

This is a prospective, non-randomized, single-arm, multi-centre surveillance study to be conducted in Europe.

The Surveillance is designed as a study, where

- ARISE AV is prescribed in the usual manner in accordance with the terms of the approval.

- Assignment of the patient to a particular therapeutic strategy is not decided in advance by this Surveillance Protocol but falls within current practice and the prescription of ARISE AV is clearly separated from the decision to include the patient in the Surveillance.

- No additional diagnostic or monitoring procedures shall be applied to the patients.

- and epidemiological methods shall be used for the analysis of collected data.


Recruitment information / eligibility

Status Completed
Enrollment 144
Est. completion date March 2019
Est. primary completion date January 2019
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

i. Indication for aortic valve replacement according to current medical guidelines in valvular heart disease

ii. Informed consent of legal guardians or patients, assent of patients

Exclusion Criteria:

i. The patient has not provided Surveillance informed consent.

ii. The patient shall not suffer from:

- generalized connective tissue disorders (eg, Marfan syndrome), or .

- active rheumatic disorders, or

- severe asymmetric calcification of the valve ring.

iii. The coronary arteries of the patient shall not be in abnormal position or heavily calcified.

iv. Patients shall not show hypersensitivity against sodium dodecyl sulphate (SDS), sodium desoxycholate (SDC), human collagen (or other elastic fibers) or Benzonase®.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Decellularized human heart valves
Decellularized human aortic heart valves

Locations

Country Name City State
Belgium Universitair Ziekenhuis Leuven, UZL Leuven
Germany University of Düsseldorf, Department of Cardiovascular Surgery Düsseldorf
Germany Hannover Medical School Hannover
Italy Azienda Ospedaliera di Padova, U.O.C. di Cardiochirurgia Pediatrica e Cardiopatie Congenite Padova
Netherlands Leids Universitair Medisch Centrum, LUMC Leiden
Spain University Hospital Clinic de Barcelona, Cardiovascular Surgery administrative area Barcelona
Switzerland Kinderspital Zürich Zürich
United Kingdom Royal Brompton and Harefield National Health Service Trust London

Sponsors (9)

Lead Sponsor Collaborator
corlife Azienda Ospedaliera di Padova, Hannover Medical School, Heinrich-Heine University, Duesseldorf, Hospital Clinic of Barcelona, Leiden University Medical Center, Royal Brompton & Harefield NHS Foundation Trust, Universitaire Ziekenhuizen Leuven, Vienna General Hospital

Countries where clinical trial is conducted

Belgium,  Germany,  Italy,  Netherlands,  Spain,  Switzerland,  United Kingdom, 

References & Publications (1)

Horke A, Tudorache I, Laufer G, Andreas M, Pomar JL, Pereda D, Quintana E, Sitges M, Meyns B, Rega F, Hazekamp M, Hübler M, Schmiady M, Pepper J, Rosendahl U, Lichtenberg A, Akhyari P, Jashari R, Boethig D, Bobylev D, Avsar M, Cebotari S, Haverich A, Sari — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Cardiovascular Adverse Reactions (AR) Rate of cardiovascular AR, e.g. all-cause mortality, major stroke, life-threatening (or disabling) bleeding, acute kidney injury—stage 3 (including renal replacement therapy), peri-procedural myocardial infarction, major vascular complication, repeat procedure for valve-related dysfunction (surgical or interventional therapy). up to 24 months
Primary Freedom from valve dysfunction at end of the study Echocardiographic studies should be obtained and analyzed at discharge and at 3, 6 Months and at annual follow-ups. The requested variables include peak and mean systolic gradient, using pw and cw doppler, in the left ventricular outflow tract, respective the aortic valve. The echo evaluation (videotape or CD) should remain at the Surveillance site, but be available to corlife Surveillance personnel upon request. The MRIs will be analyzed by the MRI Core Laboratory at Medical School in Hannover for potential valvular stenosis, via phase contrast flow measurements in the aorta and for valvular competence, via phase contrast flow measurements and by ventricular volumetry. MRI cine images will be used to visualize the Surveillance valve in patients with poor echocardiographic windows. up to 24 months
Secondary Evaluation of composite blood parameters The following data should be collected: Hb, LDH, Haptoglobin, CRP, Leukocytes. Blood studies should be performed within 7 days preoperatively and at discharge. Blood data will support the absence/presence of related AR. For example, haemolysis should be reported as an adverse event if anaemia is present; however, in the absence of anaemia, haemolysis will be considered to be compensated and does not require reporting. Time to events, such as death, reoperation including explantation will be evaluated for those outcomes, calculated from the date of operation. up to 24 months
Secondary Time to reoperation and / or death Time to events, such as death, reoperation including explantation will be evaluated for those outcomes, calculated from the date of operation up to 24 months
Secondary Evaluation of composite valve measures Diameters of ARISE AV at end of the Surveillance will be analyzed in comparison to diameters at implantation and to age matched reference values. Preoperative non-invasive data on left ventricular size and function, such as left ventricular end diastolic, end systolic volume, ejection fraction and ventricular mass will be derived from MRI and compared to postoperative status. up to 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Completed NCT01178710 - Effect of Simvastatin on Cardiac Function N/A
Completed NCT01426776 - Effect of Heart Valve Replacement on Cheyne-Stokes Respiration N/A
Completed NCT00581399 - A Randomized Multicenter Clinical Study On the High Vacuum Body Cavity Drainage System Following Open Heart Surgery Phase 2
Withdrawn NCT00187304 - ACTION - Anticoagulation Treatment Influence on Post-operative Patients Phase 4
Terminated NCT00700947 - Using Beta Blockers to Treat Mitral Regurgitation Phase 1
Recruiting NCT02574650 - Early Feasibility of the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) Also Known as TriAlign™. N/A
Recruiting NCT02650388 - Frailty and Cognitive Function Assessment of TAVI Patients Phase 4
Completed NCT01996657 - D-dimer and Oral Anticoagulation Therapy in Patients With Mechanical Valve Replacement N/A
Terminated NCT00598936 - A Prospective Study With a New Device for the Monitoring of Cerebral Oxygenation on Cardiac Surgery Patients Phase 1
Terminated NCT01812174 - On-X Heart Valve - 17mm Aortic and 23mm Mitral N/A
Recruiting NCT03225612 - Safety and Performance of the Trialign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) N/A
Completed NCT01384643 - Effect of Propofol on Renal Injury in Patients Undergoing Valvular Heart Surgery Phase 4
Completed NCT01558765 - CopenHeartVR - Integrated Rehabilitation of Patients After Heart Valve Surgery Phase 2
Active, not recruiting NCT00291525 - Randomized On-X Anticoagulation Trial N/A
Completed NCT02867930 - Comparative Effects of Dexmedetomidine and Ketofol for Sedation in Patients Undergoing Trans-esophageal Echocardiography Phase 4
Recruiting NCT02478008 - A Clinical Study of the CardiAQ™ TMVI System (Transapical DS) N/A
Completed NCT02790008 - Magnetic Resonance Imaging and Fibrosis
Completed NCT02587039 - An Intervention to Reduce Delirium After Cardiac Surgery N/A
Recruiting NCT01855737 - The Study of Warfarin Maintenance Dose in Chinese Patients Phase 4

External Links